<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37012058</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>05</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2053-8790</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Lupus science &amp; medicine</Title><ISOAbbreviation>Lupus Sci Med</ISOAbbreviation></Journal><ArticleTitle>Autoantibody-based subgroups and longitudinal seroconversion in juvenile-onset systemic lupus erythematosus.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e000834</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/lupus-2022-000834</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To explore the clinical value of autoantibody-based subgroup framework and the trend of autoantibody fluctuation in juvenile-onset SLE (JSLE).</AbstractText><AbstractText Label="METHODS">Eighty-seven patients with JSLE were retrospectively collected and divided into subgroups via a two-step cluster based on the status of nine autoantibodies (double-stranded-DNA (dsDNA), nucleosome, histone, ribosomal P protein, Smith (Sm), u1-ribonucleoprotein (RNP), Sj&#xf6;gren's syndrome antigen A (SSA)/Ro52, SSA/Ro60, Sj&#xf6;gren's syndrome antigen B (SSB)/La). The final model selected in this study was based on adequate goodness of fit of the Silhouette coefficient and clinical interpretability. Clinical manifestations, organ involvements and disease activity were compared among the subgroups. Fluctuation in autoantibody status was also collected and analysed. Flare-free survival rates of the patients with positive/negative seroconversion and patients without seroconversion were studied by the Kaplan-Meier method and compared using a log-rank test.</AbstractText><AbstractText Label="RESULTS">Two clusters were identified: subgroup 1 (positive anti-Sm/RNP group) and subgroup 2 (negative anti-Sm/RNP group). There were more lupus nephritis (LN) and neuropsychiatric SLE (NPSLE) cases in subgroup 1 than in subgroup 2. Patients in subgroup 1 exhibited higher SLE Disease Activity Index scores compared with those in subgroup 2. Furthermore, anti-ribosomal P protein (61.1%), anti-nucleosome (58.3%) and anti-dsDNA (54%) were most commonly positive autoantibodies. A progressive decrease in the frequency of patients with positive results was demonstrated during the follow-up years. The decrease was notable for anti-dsDNA, anti-nucleosome and anti-ribosomal P protein (remaining 27.27%, 38.89% and 45.00% positive in the fifth year, respectively). While for those negative at baseline diagnosis, the decrease in the frequency of negative results was progressive but modest. Kaplan-Meier curve showed that the flare-free survival of patients with positive seroconversion was significantly lower than those without seroconversion and those with negative seroconversion (p&lt;0.001).</AbstractText><AbstractText Label="CONCLUSIONS">In children with SLE, subgroups based on autoantibody profile can be applied to differentiate phenotypes and disease activity. Two important organ involvements, LN and NPSLE, are more common in patients with positive anti-Sm/RNP autoantibodies. Positive seroconversion may provide a valuable perspective for assessing flare, and it is worthwhile to retest the array of autoantibodies during follow-up.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bao</LastName><ForeName>Shengfang</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-5529-135X</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology &amp; Immunology, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Hua</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Rheumatology &amp; Immunology, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Yingying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Rheumatology &amp; Immunology, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ding</LastName><ForeName>Fei</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Rheumatology &amp; Immunology, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Zhen</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Rheumatology &amp; Immunology, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Xuemei</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Rheumatology &amp; Immunology, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Chenxi</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Rheumatology &amp; Immunology, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Jingyi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Rheumatology &amp; Immunology, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Yanliang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Rheumatology &amp; Immunology, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China jinyanliang@scmc.com.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lupus Sci Med</MedlineTA><NlmUniqueID>101633705</NlmUniqueID><ISSNLinking>2053-8790</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000974">Antibodies, Antinuclear</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-49-2</RegistryNumber><NameOfSubstance UI="D004247">DNA</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012859" MajorTopicYN="Y">Sjogren's Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069078" MajorTopicYN="N">Seroconversion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000974" MajorTopicYN="N">Antibodies, Antinuclear</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004247" MajorTopicYN="N">DNA</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antibodies, Anticardiolipin</Keyword><Keyword MajorTopicYN="N">Lupus Erythematosus, Systemic</Keyword><Keyword MajorTopicYN="N">Lupus Nephritis</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>3</Day><Hour>21</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37012058</ArticleId><ArticleId IdType="pmc">PMC10083868</ArticleId><ArticleId IdType="doi">10.1136/lupus-2022-000834</ArticleId><ArticleId IdType="pii">10/1/e000834</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aringer M, Costenbader K, Daikh D, et al. . 2019 European League against rheumatism/american College of rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol 2019;71:1400&#x2013;12. 10.1002/art.40930</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40930</ArticleId><ArticleId IdType="pmc">PMC6827566</ArticleId><ArticleId IdType="pubmed">31385462</ArticleId></ArticleIdList></Reference><Reference><Citation>Massias JS, Smith EMD, Al-Abadi E, et al. . Clinical and laboratory characteristics in juvenile-onset systemic lupus erythematosus across age groups. Lupus 2020;29:474&#x2013;81. 10.1177/0961203320909156</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203320909156</ArticleId><ArticleId IdType="pmc">PMC7528537</ArticleId><ArticleId IdType="pubmed">32233733</ArticleId></ArticleIdList></Reference><Reference><Citation>Oni L, Wright RD, Marks S, et al. . Kidney outcomes for children with lupus nephritis. Pediatr Nephrol 2021;36:1377&#x2013;85. 10.1007/s00467-020-04686-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00467-020-04686-1</ArticleId><ArticleId IdType="pmc">PMC8084759</ArticleId><ArticleId IdType="pubmed">32725543</ArticleId></ArticleIdList></Reference><Reference><Citation>To CH, Petri M. Is antibody clustering predictive of clinical subsets and damage in systemic lupus erythematosus? Arthritis Rheum 2005;52:4003&#x2013;10. 10.1002/art.21414</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.21414</ArticleId><ArticleId IdType="pubmed">16320348</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis MJ, McAndrew MB, Wheeler C, et al. . Autoantibodies targeting TLR and smad pathways define new subgroups in systemic lupus erythematosus. J Autoimmun 2018;91:1&#x2013;12. 10.1016/j.jaut.2018.02.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2018.02.009</ArticleId><ArticleId IdType="pubmed">29576246</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaz-Gallo L-M, Oke V, Lundstr&#xf6;m E, et al. . Four systemic lupus erythematosus subgroups, defined by autoantibodies status, differ regarding HLA-DRB1 genotype associations and immunological and clinical manifestations. ACR Open Rheumatol 2022;4:27&#x2013;39. 10.1002/acr2.11343</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr2.11343</ArticleId><ArticleId IdType="pmc">PMC8754019</ArticleId><ArticleId IdType="pubmed">34658170</ArticleId></ArticleIdList></Reference><Reference><Citation>Faria AC, Barcellos KSA, Andrade LEC. Longitudinal fluctuation of antibodies to extractable nuclear antigens in systemic lupus erythematosus. J Rheumatol 2005;32:1267&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">15996063</ArticleId></ArticleIdList></Reference><Reference><Citation>Frodlund M, Wetter&#xf6; J, Dahle C, et al. . Longitudinal anti-nuclear antibody (ANA) seroconversion in systemic lupus erythematosus: a prospective study of Swedish cases with recent-onset disease. Clin Exp Immunol 2020;199:245&#x2013;54. 10.1111/cei.13402</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cei.13402</ArticleId><ArticleId IdType="pmc">PMC7008226</ArticleId><ArticleId IdType="pubmed">31778219</ArticleId></ArticleIdList></Reference><Reference><Citation>Nylund KL, Asparouhov T, Muth&#xe9;n BO. Deciding on the number of classes in latent class analysis and growth mixture modeling: a Monte Carlo simulation study. Structural Equation Modeling: A Multidisciplinary Journal 2007;14:535&#x2013;69. 10.1080/10705510701575396</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10705510701575396</ArticleId></ArticleIdList></Reference><Reference><Citation>Rousseeuw PJ. Silhouettes: a graphical aid to the interpretation and validation of cluster analysis. Journal of Computational and Applied Mathematics 1987;20:53&#x2013;65. 10.1016/0377-0427(87)90125-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0377-0427(87)90125-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg MC. Updating the American College of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725. 10.1002/art.1780400928</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780400928</ArticleId><ArticleId IdType="pubmed">9324032</ArticleId></ArticleIdList></Reference><Reference><Citation>Trindade VC, Carneiro-Sampaio M, Bonfa E, et al. . An update on the management of childhood-onset systemic lupus erythematosus. Paediatr Drugs 2021;23:331&#x2013;47. 10.1007/s40272-021-00457-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40272-021-00457-z</ArticleId><ArticleId IdType="pmc">PMC8270778</ArticleId><ArticleId IdType="pubmed">34244988</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodsaward P, Chottawornsak N, Suwanchote S, et al. . The clinical significance of antinuclear antibodies and specific autoantibodies in juvenile and adult systemic lupus erythematosus patients. Asian Pac J Allergy Immunol 2021;39. 10.12932/AP-211218-0465</Citation><ArticleIdList><ArticleId IdType="doi">10.12932/AP-211218-0465</ArticleId><ArticleId IdType="pubmed">31012595</ArticleId></ArticleIdList></Reference><Reference><Citation>Pisetsky DS, Lipsky PE. New insights into the role of antinuclear antibodies in systemic lupus erythematosus. Nat Rev Rheumatol 2020;16:565&#x2013;79. 10.1038/s41584-020-0480-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-020-0480-7</ArticleId><ArticleId IdType="pmc">PMC8456518</ArticleId><ArticleId IdType="pubmed">32884126</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Mughales JA. Anti-nuclear antibodies patterns in patients with systemic lupus erythematosus and their correlation with other diagnostic immunological parameters. Front Immunol 2022;13:850759. 10.3389/fimmu.2022.850759</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.850759</ArticleId><ArticleId IdType="pmc">PMC8964090</ArticleId><ArticleId IdType="pubmed">35359932</ArticleId></ArticleIdList></Reference><Reference><Citation>Tincani A, Andreoli L, Chighizola C, et al. . The interplay between the antiphospholipid syndrome and systemic lupus erythematosus. Autoimmunity 2009;42:257&#x2013;9. 10.1080/08916930902827918</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08916930902827918</ArticleId><ArticleId IdType="pubmed">19811269</ArticleId></ArticleIdList></Reference><Reference><Citation>Groot N, de Graeff N, Avcin T, et al. . European evidence-based recommendations for diagnosis and treatment of paediatric antiphospholipid syndrome: the share initiative. Ann Rheum Dis 2017;76:1637&#x2013;41. 10.1136/annrheumdis-2016-211001</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2016-211001</ArticleId><ArticleId IdType="pubmed">28473426</ArticleId></ArticleIdList></Reference><Reference><Citation>von Scheven E, Glidden DV, Elder ME. Anti-Beta2-Glycoprotein I antibodies in pediatric systemic lupus erythematosus and antiphospholipid syndrome. Arthritis Rheum 2002;47:414&#x2013;20. 10.1002/art.10510</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.10510</ArticleId><ArticleId IdType="pubmed">12209489</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahluwalia J, Singh S, Naseem S, et al. . Antiphospholipid antibodies in children with systemic lupus erythematosus: a long-term clinical and laboratory follow-up status study from northwest India. Rheumatol Int 2014;34:669&#x2013;73. 10.1007/s00296-013-2736-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-013-2736-x</ArticleId><ArticleId IdType="pubmed">23563494</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x130;lgen U, Yayla ME, Ate&#x15f; A, et al. . Antiphospholipid antibodies and non-thrombotic manifestations of systemic lupus erythematosus. Lupus 2018;27:665&#x2013;9. 10.1177/0961203317734924</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203317734924</ArticleId><ArticleId IdType="pubmed">29050535</ArticleId></ArticleIdList></Reference><Reference><Citation>Raissi TC, Hewson C, Pope JE. Repeat testing of antibodies and complements in systemic lupus erythematosus: when is it enough? J Rheumatol 2018;45:827&#x2013;34. 10.3899/jrheum.161365</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.161365</ArticleId><ArticleId IdType="pubmed">29657153</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherman MA, Gunawardana A, Amirault JP, et al. . Autoantibody cluster analysis in juvenile lupus nephritis. Clin Rheumatol 2022;41:2375&#x2013;81. 10.1007/s10067-022-06146-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-022-06146-7</ArticleId><ArticleId IdType="pubmed">35347489</ArticleId></ArticleIdList></Reference><Reference><Citation>Fava A, Guthridge C, Kheir J, et al. . Autoantibody trajectories associate with classification and treatment response in lupus nephritis. Arthritis Rheumatol
2022;74.(suppl 9) Available: https://acrabstracts.org/abstract/autoantibody-trajectories-associate-with-classification-and-treatment-response-in-lupus-nephritis/</Citation></Reference><Reference><Citation>Arbuckle MR, McClain MT, Rubertone MV, et al. . Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003;349:1526&#x2013;33. 10.1056/NEJMoa021933</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa021933</ArticleId><ArticleId IdType="pubmed">14561795</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma K, Du W, Wang X, et al. . Multiple functions of B cells in the pathogenesis of systemic lupus erythematosus. Int J Mol Sci 2019;20:23. 10.3390/ijms20236021</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20236021</ArticleId><ArticleId IdType="pmc">PMC6929160</ArticleId><ArticleId IdType="pubmed">31795353</ArticleId></ArticleIdList></Reference><Reference><Citation>Soni C, Reizis B. Self-DNA at the epicenter of SLE: immunogenic forms, regulation, and effects. Front Immunol 2019;10:1601. 10.3389/fimmu.2019.01601</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.01601</ArticleId><ArticleId IdType="pmc">PMC6637313</ArticleId><ArticleId IdType="pubmed">31354738</ArticleId></ArticleIdList></Reference><Reference><Citation>Oke V, Brauner S, Larsson A, et al. . IFN-&#x3bb;1 with th17 axis cytokines and IFN-&#x3b1; define different subsets in systemic lupus erythematosus (SLE). Arthritis Res Ther 2017;19:139. 10.1186/s13075-017-1344-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-017-1344-7</ArticleId><ArticleId IdType="pmc">PMC5471711</ArticleId><ArticleId IdType="pubmed">28619037</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenan-Barrett J, Doolan G, Shah D, et al. . Biomarkers associated with organ-specific involvement in juvenile systemic lupus erythematosus. Int J Mol Sci 2021;22:14. 10.3390/ijms22147619</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22147619</ArticleId><ArticleId IdType="pmc">PMC8306911</ArticleId><ArticleId IdType="pubmed">34299237</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>